Notwithstanding these provisions, the IRA’s impact on commercialization and competition remains largely uncertain.
All entries for: Dermatology
March 9, 2026
Septerna Inc
Neutral Outlook
South San Francisco, CA
51-200 employees
It is unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry.
Disease Area: Dermatology, Endocrinology, Immune Diseases, Metabolic Diseases
Drug Type: Small Molecule
March 5, 2026
HUTCHMED (China) Ltd
Negative Outlook
Hong Kong
1,001-5,000 employees
The IRA, or other federal or state laws, could affect the market conditions for, or pricing or reimbursement of, our products. There is no assurance that federal or state health care reform will not adversely affect our future business and financial results.
Disease Area: Dermatology, Hematology, Immune Diseases, Oncology
Drug Type: Biologic, Small Molecule
March 3, 2026
Anaptysbio/CA
Neutral Outlook
San Diego, CA
1-50 employees
Healthcare reform initiatives include the enactment of the Inflation Reduction Act (“IRA”), which, among other things, allows the HHS to negotiate the selling price of certain drugs and biologics that CMS reimburses under Medicare Part B and Part D, although only high-expenditure single-source drugs that have been approved for at least seven years (11 years for biologics) can be selected by CMS for negotiation, with the negotiated price taking effect two years after the selection year. For 2026, the first year in which negotiated prices become effective, CMS selected 10 high-cost Medicare Part D products in 2023, negotiations began in 2024, and the negotiated maximum fair price for each product has been announced.
Disease Area: Dermatology, Gastrointestinal, Immune Diseases
Drug Type: Biologic
February 27, 2026
Amneal Pharmaceuticals Inc
Negative Outlook
Bridgewater, NJ
5,001-10,000 employees
The drug pricing reforms in the IRA have impacted, and may impact in the future, the prices of certain of our products.
Disease Area: Cardiology, Dermatology, Endocrinology, Hematology, Infectious Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
February 27, 2026
Aldeyra Therapeutics Inc
Neutral Outlook
Lexington, MA
1-50 employees
For that and other reasons, it is currently unclear how the IRA will be effectuated but it is likely to have a significant impact on the pharmaceutical industry.
Disease Area: Dermatology, Immune Diseases, Neurological Diseases, Oncology, Rare Diseases
Drug Type: Small Molecule
February 26, 2026
Kymera Therapeutics
Neutral Outlook
Watertown, MA
201-500 employees
The effect of IRA on our business and the pharmaceutical industry in general is not yet known.
Disease Area: Dermatology, Gastrointestinal, Immune Diseases, Oncology, Respiratory Diseases
Drug Type: Small Molecule
February 25, 2026
Arcus Biosciences, Inc.
Neutral Outlook
Hayward, CA
501-1,000 employees
For that and other reasons, it is currently unclear how the IRA will be effectuated, or the impact of the IRA on our business.
Disease Area: Dermatology, Immune Diseases, Oncology
Drug Type: Biologic, Small Molecule